Baum C L
Department of Medicine, University of Illinois at Chicago, 60612, USA.
JPEN J Parenter Enteral Nutr. 2001 May-Jun;25(3):114-9. doi: 10.1177/0148607101025003114.
Organ transplantation has become a common and effective approach to the management of patients with organ failure. The improvement in long-term survival has resulted in the emergence of cardiovascular disease as the primary cause of death in renal transplant patients and a significant complication in other organ recipients. A number of factors explain this trend, including a high incidence of hypertension, posttransplant diabetes, hyperlipidemia, and obesity-risk factors that are mediated by direct effects of immunosuppressive medications. Weight gain posttransplant affects approximately 50% of patients and represents a significant problem because of the potential synergism between obesity and immunosuppressive medication-induced effects on cardiovascular disease risk factor development. This review discusses the incidence and implications of cardiovascular disease risk factors in organ transplant recipients, strategies for clinical management, and future research directions.
器官移植已成为治疗器官衰竭患者的一种常见且有效的方法。长期存活率的提高导致心血管疾病成为肾移植患者的主要死亡原因,并成为其他器官移植受者的一个重大并发症。多种因素可以解释这一趋势,包括高血压、移植后糖尿病、高脂血症和肥胖的高发病率,这些危险因素是由免疫抑制药物的直接作用介导的。移植后体重增加影响了约50%的患者,并且由于肥胖与免疫抑制药物对心血管疾病危险因素发展的潜在协同作用,这成为一个重大问题。本综述讨论了器官移植受者心血管疾病危险因素的发生率和影响、临床管理策略以及未来的研究方向。